pharma · SBRT · Covid19 · GRTX
Kailera Therapeutics
Galera Therapeutics
Kailera Therapeutics is a pharma organization headquartered in Waltham, USA. It trades on NYSE under ticker GRTX. Primary therapeutic focus areas include SBRT, Covid19, Head and Neck Cancer, Oral Mucositis, Esophagitis.
Company details
- Status
- Public
- HQ
- Waltham, Massachusetts, United States
- Founded
- 2024
- Employees
- 153
- Programs
- 17
- Drugs
- 7
- Patents
- 23
GC4711 30 mg IV
Phase 1 · small molecule · Healthy Volunteers
GC4711 30 mg IV for Healthy Volunteers is a Phase 1 program (small_molecule) at Galera Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code GTI-4711-001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Galera Therapeutics
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Healthy Volunteers
- Status
- completed
- Trials
- 1